Supplementary Data Tables S1-S4 from Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors

Autor: Jason J. Luke, Steven J. Chmura, Sean P. Pitroda, Ralph R. Weichselbaum, Mark D. Hoffman, Julia Dai, Linda A. Janisch, Robyn Hseu, Hedy L. Kindler, Everett E. Vokes, Peter H. O'Donnell, Olwen M. Hahn, Blase N. Polite, Rita Nanda, Mark J. Ratain, John W. Moroney, Ami V. Desai, Chih-Yi Liao, Theodore G. Karrison, Gini F. Fleming, Corey C. Foster
Rok vydání: 2023
DOI: 10.1158/1078-0432.22481121
Popis: Table S1 shows the included solid tumor histologies for enrolled patients. Table S2 shows at least possibly treatment-related grade 2 or greater adverse events among patients remaining on study for at least 3 months. Table S3 shows all adverse events among patients remaining on study for at least 3 months. Table S4 shows the proportion of patients receiving stereotactic body radiation therapy to all RECIST target lesions and all clinically or radiographically apparent metastases by response category.
Databáze: OpenAIRE